AstraZeneca moves to profit from its Covid-19 vaccine

UK drugmaker will generate modest profits from new orders

The AstraZeneca vaccine will continue to be sold at cost for developing nations. Picture: Dan Linehan

AstraZeneca is moving to profit from the Covid-19 vaccine it developed with the University of Oxford, after watching Pfizer and Moderna reap huge returns over the past year of the pandemic.

The UK drugmaker will start generating modest profits from the shot as new orders are received, AstraZeneca said. The vaccine will continue to be sold at cost for developing nations.